System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Jean-Jacques Parienti is an expert in Critical care at Centre Hospitalier Universitaire de Caen (France). Jean-Jacques Parienti has authored 340 publications, the most recent in 2026, and is an investigator in 39 clinical trials, 5 of them ongoing. SLR score: 1,564 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Jean-Jacques Parienti Centre Hospitalier Universitaire de Caen France
1 564 ScienceLeadR Reputation 1564

Unlock

Register Login
Network Map

Critical care

Subspecialties: Infectiology - Cardiology - Surgery

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2002 - 2026
Source: PubMed

Centre Hospitalier Universitaire de Caen

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 340

Citations

Citations: 10 771 1st author: 43 Last author: 38 Unique author: 25

Main journals

Clin Infect Dis 18
Intensive Care Med 18
J Antimicrob Chemother 11
AIDS 9
Crit Care Med 9

Best Journals

JAMA 8
N Engl J Med 8
Intensive Care Med 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Understanding the Clone-Censor-Weight Method in Observational Studies of Antibiotic Duration.
PMID 42403163 — clone cells, communicable diseases		Clin Infect Dis20260
Sensoriality of emollient creams: can sensory experience compromise blinding in trials?
PMID 42222691 — skin, emollients		Skin Health Dis20260
Early bictegravir failure and emergence of R263K-mediated class-wide HIV integrase inhibitors resistance linked to over-the-counter supplement use.
PMID 42153390 — hiv integrase, drug therapy, hiv, hiv integrase inhibitors, integrase inhibitors, integrases		J Antimicrob Chemother20260
Short-cycle 4-days-per-week maintenance two-drug therapy in people living with HIV (ANRS-177 DUETTO): a randomised, open-label, multicentre, non-inferiority trial.
PMID 42140217 — cd4 lymphocyte count, pharmaceutical preparations, drug therapy, maintenance, hiv, therapeutics, hiv infections		Lancet HIV20260
Selected Industry Highlights From IDWeek 2025.
PMID 42139090 — obesity, therapeutics, communicable diseases		Clin Infect Dis20260

Clinical Studies 39

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 5 Study Director: 1

By phase:

N/A 13
Phase 3 11
Phase 4 7
Phase 2 3
Phase 2/Phase 3 3
Phase 1 2

By status:

Completed 24
Unknown 7
Recruiting 3
Terminated 3
Active not recruiting 1
Not yet recruiting 1

By type:

Interventional 34
Observational 5

By Monocentric/Multicentric:

monocentric 19
multicentric2to4 8
multicentric5to9 4
multicentricup10 8

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

5 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Na ve Persons with HIV 1 (INNOVATE Study)
2025-521918-26-00 — hiv-1, tenofovir, safety, hiv, emtricitabine, therapeutics, hiv infections, infections		Phase 2Active not recruiting2026
Prospective Multicenter Study of the Relationship Between Virological Effectiveness and Compliance in HIV 1 infected Patients Treated With Bictegravir
NCT06902142 — hiv-1, treatment adherence and compliance, pharmaceutical preparations, micro-electrical-mechanical systems, hiv, research, therapeutics, art therapy, forgiveness		N/ARecruiting2025
DOR TDF 3TC Switch With M184V I in People With Controlled HIV (Drive Off Road)
NCT06034938 — tenofovir, pilots, lamivudine, tablets, maintenance, fumarates, hiv, therapeutics, mutation		Phase 2Recruiting2024
Safety and Efficacy of Apixaban Versus Warfarin in Peritoneal Dialysis Patients With Non Valvular Atrial Fibrillation a Prospective Randomised Open label Blinded End point Trial (APIDP2)
NCT06045858 — anticoagulants, safety, hemorrhage, peritoneal dialysis, atrial fibrillation, kidney failure, chronic, warfarin, apixaban		Phase 3Not yet recruiting2024
Dual Therapy in HIV Patients in 4 Days a Week Versus 7 Days a Week
NCT04867083 — darunavir, hiv-1, lamivudine, anti-retroviral agents, viral load, hiv, rilpivirine, therapeutics, hiv infections, infections		Phase 3Recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS